01/09/2020 Ursodeoxycholic acid for treating primary biliary cirrhosis
The Ministry of Health’s Drug Advisory Committee has recommended:
- Ursodeoxycholic acid 250 mg capsule, 500 mg tablet and 50 mg/ml suspension for treating primary biliary cirrhosis in patients without decompensated hepatic cirrhosis.
Subsidy status
RUrsodeoxycholic acid 250 mg capsule, 500 mg tablet and 50 mg/ml suspension are recommended for inclusion on the MOH Standard Drug List (SDL).
RUrsodeoxycholic acid 50 mg/ml suspension does not have regulatory approval with the Health Sciences Authority (HSA). The responsibility of prescribing an unregistered product to patients lies with the treating clinician. Before treatment is started, it is important to consider the availability of other suitable registered alternatives and inform the patient or their carer that the product is unregistered.